==Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65
Founded 201
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.

==Silvercrest Asset Management (SAMG)

Silvercrest Asset Management Group Inc. completed its initial public offering on June 27, 2013, trading on the NASDAQ under the ticker symbol SAMG.

Founded in 2002, the New York-based wealth management firm focuses on ultra-high-net-worth individuals, families, and institutional investors.

IPO and Offering Details

Date: June 27, 2013 (effective June 26, 2013)
Exchange / Ticker: NASDAQ: SAMG
Shares Offered: ~4.8 million shares
Price Range: $12 to $14 per share
Capital Raised: ~$62 million
Lead Underwriters: Sandler O’Neill + Partners and Raymond James

Initial Delay: Silvercrest initially filed for a $55 million IPO in September 2012, but formally withdrew it in November 2012 citing unfavorable market valuations.

==RoboStrategy (BOT) : 2-month performance

 RoboStrategy, Inc. debuted on the public market on May 11, 2026, listing on the NASDAQ under the ticker symbol BOT. Rather than a standard operating company IPO, it launched as a specialized closed-end investment fund.

• https://robostrategy.co/

Fund Structure and Purpose

Vehicle Type: Closed-end management investment company.
Core Objective: Provides public market and retail investors access to private, pre-IPO, and public robotics and physical AI companies.
Investment Access: Targets high-profile robotics startups that have historically been restricted to venture capital funds.

Portfolio Holdings

Featured Startups: Includes private sector leaders such as Figure AI, Apptronik, Standard Bots, Dyna Robotics, and Dexmate.
Strategy: Focuses on a high-conviction portfolio of 20 to 30 positions concentrated on hardware, humanoids, and physical artificial intelligence.

Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

==Parabilis Medicines (PBLS) began trading on the Nasdaq on Wed 10 June 26

Parabilis Medicines is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them.  

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 145
• Founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 
• Formerly known as Fog Pharma
• Headquartered in Cambridge, Massachusetts
• https://parabilismed.com/

===Quantinuum (QNT) began trading on the Nasdaq on Thur 4 June 26

 

Quantinuum is the world’s largest integrated quantum computing company, formed in late 2021 by the merger of Honeywell Quantum Solutions (hardware expertise, trapped-ion technology) and Cambridge Quantum (software, algorithms, and quantum cybersecurity).Key Facts

• Headquarters: Broomfield, Colorado (US), with major operations in Cambridge, UK, and additional sites in Germany, Japan, and elsewhere.
• Employees: Approximately 450–680 (sources vary; includes 370+ scientists and engineers, with a high proportion holding advanced degrees).
• Leadership: CEO Rajeeb Hazra; Ilyas Khan (founder of Cambridge Quantum) serves as Chief Product Officer.
• Status: Privately held until recently; it completed a major IPO in early June 2026 on Nasdaq (ticker QNT), raising significant capital at a multi-billion-dollar valuation amid strong demand. Honeywell remains a major backer.

TechnologyQuantinuum specializes in trapped-ion quantum computers, widely regarded as among the highest-performing in the industry due to high gate fidelities, full qubit connectivity, and support for mid-circuit measurements.

• H-Series (e.g., System Model H2): Features up to 56 fully connected qubits, record quantum volumes (a holistic performance metric exceeding 2 million in some reports), and >99.99% single-qubit gate fidelity. It has demonstrated milestones like the first fully fault-tolerant universal gate set.
• Roadmap: Accelerated push toward universal, fault-tolerant quantum computing by 2030, with next-generation systems like Apollo (targeting 100+ qubits). Emphasis on scalable, high-fidelity hardware combined with error correction.
• Software & Full-Stack: Includes TKET (open-source compiler), InQuanto (chemistry-focused), Quantum Origin (quantum-enhanced cybersecurity/randomness), and the Nexus platform for cloud access, emulation, and hybrid workflows. Strong integration across hardware, software, and applications.

Access is available via cloud (e.g., Azure Quantum) and direct subscriptions, with emulators for development.

Applications and Focus AreasThe company targets commercial and scientific breakthroughs in:

• Materials discovery and computational chemistry
• Drug discovery and biology
• Cybersecurity (quantum-resistant solutions)
• Optimization, AI, finance, and energy (e.g., collaborations with bp on wave physics/seismic imaging)
• Hybrid quantum-classical computing for industry use cases

It emphasizes "science-led, enterprise-driven" solutions and has partnerships with entities like RIKEN, Mitsubishi Electric, NVIDIA, JPMorgan, Synopsys, and others.

==Swarmer (SWMR) began trading on the Nasdaq on Tue 17 March 26

Swarmer makes drone-autonomy software, enabling drones to swarm, and helping operators control dozens or hundreds of drones simultaneously—making it difficult to disable the entire swarm by taking out a single drone.

The company’s technology has been deployed in Ukraine since 2023, where it has supported more than 100,000 combat missions.

• Founded 2023
• Headquarters: Austin, Texas
• Employees: 49
• getswarmer.com

Drone-tech firm Swarmer Inc. (Nasdaq: SWMR), which boasts Blackwater founder and industry veteran Erik Prince as its non-executive chairman, saw its shares rise as much as 700% in late trade Tuesday after pricing at $5 each the night before.

The company is building a software-first, AI enabled, autonomy and coordination platform for scaled unmanned combat operations. While it may sound like the script from a Terminator movie, the technology is no fantasy and in fact has already been combat tested in Ukraine since 2023 with tens of thousands of missions in the books. Currently, 42 armed forces use Swarmer for 300+ missions daily.

2026 is set to be an inflection year for the innovator, headquartered in Texas with an expected top line of approximately $20 million. Firm commitments of $16.3 million from executed contracts offer dependable visibility into earnings potential over the next 12-24 months. With strong tailwinds in place for defense equities and SWMR approaching its first revenue inflection point, the timing looks right.

Swarmer is still a small company competing with everyone from privately held drone vendors such as Shield AI and Anduril, as well as defense contractors such as Northrop Grumman (NOC) and Lockheed Martin (LMT).

Ukraine has been at the forefront of drone warfare, serving as the testing ground for the most innovative and ground-breaking battlefield technologies. Its defense industry has rapidly expanded in response to the unprecedented scale of the conflict: in 2025 alone, Ukraine is slated to deploy close to 5,000,000 drones into active combat. This monumental scale, paired with an agility in procurement rarely seen in the defense industry, accelerates innovation and growth.

Eikon Therapeutics (EIKN) began trading on the Nasdaq on Thur 5 Feb 26

• Sector: HealthcareIndustry: Biotechnology
• Incorporated in 2019 
• HQ in Millbrae, California
• https://www.eikontx.com/

Eikon Therapeutics priced 21,177,600 share IPO (upgraded from 17.7 mln prior) at $18.00 per share, at the high end of the $16-18 expected range

Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024

Ticker: EIKN

At $381 million, Eikon looks set to be the largest biotech IPO since 2024, overtaking Aktis Oncology’s $318 million offering last month.

The California-based company has already set out its plans for spending the proceeds, with the biggest priority labeled as the clinical development of EIK1001. The toll-like receptor 7 and 8 agonist immune modulator, which Eikon acquired from Seven and Eight Biopharmaceuticals, is currently being tested in a phase 2/3 trial in combination with Keytruda for advanced melanoma and a phase 2/3 study for non-small cell lung cancer.

Behind EIK1001 is a pair of PARP1 inhibitors, dubbed EIK1003 and EIK1004, which Eikon licensed from Chinese biotech Impact Therapeutics. These candidates are being trialed in phase 1/2 studies for ovarian, breast, prostate and pancreatic cancers, with EIK1004 also being assessed against brain metastases and primary brain malignancies due to its ability to cross the blood-brain barrier.

The fourth clinical candidate is an in-house WRN helicase inhibitor called EIK1005, which is in phase 1/2 development for solid tumors.

Kodiak AI (KDK) began trading on the Nasdaq on Thur 25 Sept 25

Kodiak Robotics, Inc. builds and operates self-driving trucks. The company delivers freight for its customers between Dallas-Fort Worth and Houston. It offers solutions in the areas of updating automated drivers, a network of transfer points facilitates, and fleet management tools. 

• Sector: Industrials
• Industry: Farm & Heavy Construction Machinery
• Founder and CEO Don Burnette
• Incorporated in 2018 
• HQ based in Mountain View, California, with an operations center in Lancaster, Texas
• https://kodiak.ai

Kodiak AI (KDK) began publicly trading on the Nasdaq via a SPAC deal (Special Purpose Acquisition Company). Autonomous trucking startup Kodiak Robotics merged with Ares Acquisition Corp. II (AACT) to form the new company.

 

2 Oct 25 

 

Kodiak was founded in 2018 by industry veteran, Don Burnette, with a vision of becoming the trusted world leader in autonomous ground transportation dedicated to commercializing driverless trucking at scale. In 2024, we believe Kodiak became the first company to announce delivery of a driverless trucking product to a customer.